Loading stock data…
LH
$255.84-0.96 (-0.37%)
Market ClosedLast close May 1
Labcorp Holdings Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Labcorp Holdings Inc. in the Healthcare sector is trading at $255.84. The stock is currently 13% below its 52-week high of $293.72, remaining 4.4% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why LH maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$255.84
Potential Downside
24.1%
Whystock Fair Value$194.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$310.06+21.2%
Range$270.00 – $340.00
Fundamentals
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Strong income play. Yield provides a meaningful total return floor.
106.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.86%
Volume
Today's trading volume
514,957
Recent News
LH Q1 Deep Dive: Specialty Testing and Acquisitions Drive Growth Amid Margin Expansion
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.8% year on year to $3.54 billion. The company expects the full year’s revenue to be around $14.73 billion, close to analysts’ estimates. Its non-GAAP profit of $4.25 per share was 3.3% above analysts’ consensus estimates.
Assessing Labcorp Holdings (LH) Valuation After Recent Share Price Weakness
Labcorp Holdings at a Glance Labcorp Holdings (LH) has been drawing attention after recent share price moves, with the stock showing a 0.4% decline on the day and negative returns over the past week and month. Over the past 3 months, the stock has recorded a 5.8% decline, while the year to date performance is slightly positive at 1.7%. Over the past year, total return stands at 4.4%. See our latest analysis for Labcorp Holdings. The recent 7 day share price return of negative 3.0% and 30 day...
Labcorp Q1 Earnings Call Highlights
Labcorp (NYSE:LH) reported first-quarter 2026 results management described as a “strong start” to the year, citing revenue growth, margin expansion, and progress across strategic priorities in diagnostics, biopharma laboratory services, specialty testing, consumer health, and technology initiatives.
Labcorp (LH) Q1 2026 Earnings Call Transcript
With me today are Adam Schechter, our Chairman and Chief Executive Officer; and Julia Wang, our Executive Vice President and Chief Financial Officer. This morning, in the Events section of the Labcorp Investor Relations website at ir.labcorp.com, we posted both our press release and a supplemental financial presentation with additional information on our business and operations. Please see the Use of Adjusted Measures section in the supplemental presentation for more information regarding our use of non-GAAP financial measures.
Labcorp Holdings Inc. Q1 2026 Earnings Call Summary
Moby summary of Labcorp Holdings Inc.'s Q1 2026 earnings call